SG10201806965XA - 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer - Google Patents
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancerInfo
- Publication number
- SG10201806965XA SG10201806965XA SG10201806965XA SG10201806965XA SG10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA SG 10201806965X A SG10201806965X A SG 10201806965XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- inhibitors
- aryl
- treatment
- stem cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 201000011510 cancer Diseases 0.000 title abstract 7
- 210000000130 stem cell Anatomy 0.000 title abstract 4
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000037361 pathway Effects 0.000 title abstract 3
- 102000020233 phosphotransferase Human genes 0.000 title abstract 3
- IGXUUWYVUGBMFT-UHFFFAOYSA-N 3-methyleneoxindole Chemical class C1=CC=C2C(=C)C(=O)NC2=C1 IGXUUWYVUGBMFT-UHFFFAOYSA-N 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780263P | 2013-03-13 | 2013-03-13 | |
| US201361780248P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201806965XA true SG10201806965XA (en) | 2018-09-27 |
Family
ID=50639949
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507346PA SG11201507346PA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| SG10201806965XA SG10201806965XA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507346PA SG11201507346PA (en) | 2013-03-13 | 2014-03-13 | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160031888A1 (enExample) |
| EP (1) | EP2970206A1 (enExample) |
| JP (2) | JP6378308B2 (enExample) |
| KR (1) | KR20150127249A (enExample) |
| CN (1) | CN105408320B (enExample) |
| AU (2) | AU2014243869A1 (enExample) |
| BR (1) | BR112015022431A2 (enExample) |
| CA (1) | CA2904152A1 (enExample) |
| HK (1) | HK1220184A1 (enExample) |
| IL (1) | IL240960A0 (enExample) |
| MX (1) | MX2015011456A (enExample) |
| RU (2) | RU2019104092A (enExample) |
| SG (2) | SG11201507346PA (enExample) |
| WO (1) | WO2014160401A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104876928B (zh) * | 2015-05-07 | 2016-09-14 | 浙江司太立制药股份有限公司 | 7-氮杂吲哚啉-2-酮类化合物及其制备方法 |
| US10377749B2 (en) | 2015-08-10 | 2019-08-13 | Sumitomo Dainippon Pharma Co., Ltd. | Purification method for 5-(thiazol-4-yl)indolin-2-one derivative |
| JP6661766B2 (ja) * | 2015-11-12 | 2020-03-11 | エルジー・ケム・リミテッド | ７−アザインドリン−２−オン誘導体又はその薬学的に許容される塩を有効成分として含有する医薬組成物 |
| CN105461705B (zh) * | 2015-11-30 | 2018-04-10 | 中国医科大学 | 二苯并氮杂卓二酮类抗肿瘤化合物及其制备方法 |
| CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| CN107698593A (zh) * | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN106432228A (zh) * | 2016-09-06 | 2017-02-22 | 浙江司太立制药股份有限公司 | 含有4‑肟基‑1‑哌啶基片段的7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法 |
| CN106397436A (zh) * | 2016-09-06 | 2017-02-15 | 浙江司太立制药股份有限公司 | 5‑溴‑7‑氮杂吲哚啉‑2‑酮类化合物及其制备方法 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| TWI830180B (zh) * | 2017-06-30 | 2024-01-21 | 財團法人工業技術研究院 | 化合物之液體劑型的醫藥配方 |
| CN110357878B (zh) * | 2018-03-26 | 2022-04-12 | 武汉誉祥医药科技有限公司 | 1,3-二氢-2H-吡咯并[3,2-b]吡啶-2-酮衍生物及其医药用途 |
| HUE066783T2 (hu) | 2018-04-18 | 2024-09-28 | Constellation Pharmaceuticals Inc | Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk |
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3852754A4 (en) * | 2018-09-18 | 2022-06-15 | 1Globe Biomedical Co., Ltd. | TREATMENT OF OBESITY |
| MX2021003156A (es) * | 2018-09-18 | 2021-05-14 | 1 Globe Biomedical Co Ltd | Tratamiento para la enfermedad del higado graso no alcoholico. |
| WO2021003339A1 (en) * | 2019-07-03 | 2021-01-07 | The Regents Of The University Of Colorado, A Body Corporate | Amp-activated protein kinase inhibitors and methods of making and using the same |
| WO2021243040A2 (en) * | 2020-05-29 | 2021-12-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of grk5 and grk5 subfamily members and uses thereof |
| CN111675647B (zh) * | 2020-06-26 | 2022-03-01 | 深圳技术大学 | 2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用 |
| US20230257396A1 (en) * | 2020-07-10 | 2023-08-17 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| CA3246487A1 (en) * | 2022-01-05 | 2023-07-13 | Blossomhill Therapeutics, Inc. | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS |
| CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO1997013767A1 (de) * | 1995-10-09 | 1997-04-17 | Chemisch Pharmazeutische Forschungsgesellschaft Mbh | Heterocyclisch substituierte 1-indolcarboxamide als cyclooxygenase-2 inhibitoren |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| BR9916223A (pt) * | 1998-12-17 | 2001-09-04 | Hoffmann La Roche | 4-ariloxindóis como inibidores de cinases de proteìna jnk |
| CA2395520A1 (en) * | 1999-12-21 | 2001-06-28 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| JP2004502686A (ja) * | 2000-06-30 | 2004-01-29 | スージェン・インコーポレーテッド | ４−ヘテロアリール−３−ヘテロアリーリデニル−２−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用 |
| AR035721A1 (es) * | 2000-12-20 | 2004-07-07 | Sugen Inc | Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa |
| AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| WO2005040116A2 (en) * | 2003-10-24 | 2005-05-06 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| WO2006064044A1 (en) * | 2004-12-17 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Indolinones and their use as antiproliferative agents |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| KR101380190B1 (ko) | 2005-07-29 | 2014-04-11 | 콘서트 파마슈티컬즈, 인크. | 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 |
| BRPI0615972A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto |
| EA200801716A1 (ru) * | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途 |
| AU2007308045A1 (en) * | 2006-10-06 | 2008-04-17 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| US8299106B2 (en) | 2007-09-06 | 2012-10-30 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| BRPI0912668A2 (pt) * | 2008-05-13 | 2016-01-26 | Irm Llc | composto e composições como inibidores de quinase |
| EA201100254A1 (ru) * | 2008-07-29 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые соединения |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| US9227962B2 (en) * | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| AU2015209095A1 (en) * | 2014-01-27 | 2016-07-07 | Boston Biomedical, Inc. | Novel methods for treating cancer |
-
2014
- 2014-03-13 RU RU2019104092A patent/RU2019104092A/ru unknown
- 2014-03-13 EP EP14721620.4A patent/EP2970206A1/en not_active Withdrawn
- 2014-03-13 KR KR1020157028817A patent/KR20150127249A/ko not_active Ceased
- 2014-03-13 WO PCT/US2014/026498 patent/WO2014160401A1/en not_active Ceased
- 2014-03-13 AU AU2014243869A patent/AU2014243869A1/en not_active Abandoned
- 2014-03-13 RU RU2015143526A patent/RU2015143526A/ru not_active Application Discontinuation
- 2014-03-13 MX MX2015011456A patent/MX2015011456A/es unknown
- 2014-03-13 HK HK16108180.5A patent/HK1220184A1/zh unknown
- 2014-03-13 CA CA2904152A patent/CA2904152A1/en not_active Abandoned
- 2014-03-13 SG SG11201507346PA patent/SG11201507346PA/en unknown
- 2014-03-13 US US14/774,803 patent/US20160031888A1/en not_active Abandoned
- 2014-03-13 SG SG10201806965XA patent/SG10201806965XA/en unknown
- 2014-03-13 BR BR112015022431A patent/BR112015022431A2/pt not_active Application Discontinuation
- 2014-03-13 CN CN201480026333.XA patent/CN105408320B/zh active Active
- 2014-03-13 JP JP2016502156A patent/JP6378308B2/ja not_active Expired - Fee Related
-
2015
- 2015-08-31 IL IL240960A patent/IL240960A0/en unknown
-
2018
- 2018-07-06 JP JP2018129002A patent/JP2018168187A/ja active Pending
- 2018-09-21 AU AU2018233033A patent/AU2018233033A1/en not_active Abandoned
- 2018-11-30 US US16/206,010 patent/US20190241569A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105408320A (zh) | 2016-03-16 |
| EP2970206A1 (en) | 2016-01-20 |
| CA2904152A1 (en) | 2014-10-02 |
| KR20150127249A (ko) | 2015-11-16 |
| JP2016513656A (ja) | 2016-05-16 |
| RU2019104092A (ru) | 2019-03-20 |
| HK1220184A1 (zh) | 2017-04-28 |
| BR112015022431A2 (pt) | 2017-05-09 |
| AU2014243869A1 (en) | 2015-09-24 |
| JP6378308B2 (ja) | 2018-08-22 |
| MX2015011456A (es) | 2016-05-31 |
| RU2015143526A (ru) | 2017-04-19 |
| SG11201507346PA (en) | 2015-10-29 |
| CN105408320B (zh) | 2019-08-13 |
| US20190241569A1 (en) | 2019-08-08 |
| WO2014160401A1 (en) | 2014-10-02 |
| JP2018168187A (ja) | 2018-11-01 |
| IL240960A0 (en) | 2015-11-30 |
| AU2018233033A1 (en) | 2018-10-11 |
| US20160031888A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201806965XA (en) | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| MX2020011558A (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm. | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| NZ711376A (en) | Heteroaryl compounds and uses thereof | |
| MY173126A (en) | Arylquinazolines | |
| EA201590920A1 (ru) | Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ | |
| MX2014002683A (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| EA201591913A1 (ru) | Ингибиторы протеинкиназы | |
| MX2015012431A (es) | Pirrol amida como inhibidores. | |
| MX2012013197A (es) | Inhibidores de indazol de cinasa. | |
| MX2016001011A (es) | Derivados de quinazolin-4-ona sustituida. | |
| MX2018008362A (es) | Derivados de quinolin-2-ona. | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX2013001361A (es) | 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX345127B (es) | Derivados de tiazol. | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| UA107689C2 (xx) | ПОХІДНІ 3,4,4A,10B-ТЕТРАГІДРО-1H-ТІОПІРАНО$4, 3-c]ІЗОХІНОЛІНУ | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| MX2016007810A (es) | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. | |
| MD20150103A2 (ro) | Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10 |